日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Multi-Omics Reveal the Dysregulated Gut-Joint Axis in Knee Synovitis: Data from Two Osteoarthritis Studies in China

多组学揭示膝关节滑膜炎中肠-关节轴失调:来自中国两项骨关节炎研究的数据

Wang, Xiaoshuai; Liu, Yi; Sun, Ziying; Li, Jia; Lu, Zhihao; Huang, Jiayuan; Hu, Shixian; Cao, Peihua; Cao, Xiaolong; Li, Shangru; Ruan, Jianzhao; Liu, Jinhui; Xie, Jingyu; Sun, Haitao; Chen, Tianyu; Li, Shengfa; Zhu, Zhaohua; Wen, Zhibo; Tuan, Rocky S; Hunter, David John; Li, Zhong Alan; Shi, Dongquan; Ding, Changhai

Impact of Helicobacter pylori infection on gut and intratumoral microbiome and its association with immunotherapy response in gastrointestinal cancer

幽门螺杆菌感染对肠道和肿瘤内微生物组的影响及其与胃肠道癌症免疫治疗反应的关系

Jia, Keren; Chen, Yang; Dai, Die; Xie, Yi; Peng, Haoxin; Cao, Yanshuo; Zou, Hua; Qiu, Chuangzhao; Tan, Yan; Zhang, Xiaotian; Lu, Zhihao; Yin, Xiaochen; Peng, Zhi; Li, Jian; Shen, Lin

PD-1 antibody camrelizumab plus apatinib and SOX as first-line treatment in patients with AFP-producing gastric or gastro-esophageal junction adenocarcinoma (CAP 06): a multi-center, single-arm, phase 2 trial

PD-1抗体卡瑞利珠单抗联合阿帕替尼和SOX方案作为一线治疗AFP阳性胃癌或胃食管交界处腺癌患者的疗效(CAP 06):一项多中心、单臂II期临床试验

Wang, Yakun; Lu, Jialin; Chong, Xiaoyi; Wang, Chang; Chen, Xiaofeng; Peng, Zhi; Gu, Yanhong; Wang, Yizhuo; Wang, Xicheng; Li, Jian; Gong, Jifang; Qi, Changsong; Yuan, Jiajia; Lu, Zhihao; Lu, Ming; Zhou, Jun; Cao, Yanshuo; Chen, Yang; Zhang, Cheng; Hou, Zhiguo; Kou, Hongyi; Shen, Lin; Zhang, Xiaotian

A bispecific antibody-drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial

针对转移性食管鳞状细胞癌中 EGFR 和 HER3 的双特异性抗体药物偶联物:一项 1b 期试验

Liu, Chang; Liu, Dan; Ji, Yinghua; Sun, Meili; Gao, Shegan; Ma, Xuelei; Zhong, Diansheng; Zhu, Ji; Cao, Yanshuo; Qi, Changsong; Zhang, Miao; Zhang, Panpan; Xue, Ran; Peng, Zhi; Zhou, Jun; Ge, Sai; Lu, Ming; Yuan, Jiajia; Wang, Yakun; Wang, Zhenghang; Li, Jian; Zhang, Xiaotian; Zhu, Yi; Zhu, Hai; Xiao, Sa; Gong, Jifang; Shen, Lin; Lu, Zhihao

Reply to: "NOTCH1: A Potential New Biomarker in the Era of Immunotherapy?" and "Caution in Interpreting NOTCH1 Mutation as a Predictive Biomarker of Tislelizumab Response in Esophageal Squamous Cell Carcinoma"

回复:“NOTCH1:免疫治疗时代潜在的新生物标志物?”和“谨慎解读NOTCH1突变作为食管鳞状细胞癌替雷利珠单抗疗效预测生物标志物”

Lu, Zhihao; Du, Wenting; Jiao, Xi; Wang, Yanni; Zhang, Zhang; Shen, Lin

NOTCH1 Mutation and Survival Analysis of Tislelizumab in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Biomarker Analysis From the Randomized, Phase III, RATIONALE-302 Trial.

NOTCH1 突变与替利珠单抗治疗晚期或转移性食管鳞状细胞癌的生存分析:来自随机 III 期 RATIONALE-302 试验的生物标志物分析

Lu Zhihao, Du Wenting, Jiao Xi, Wang Yanni, Shi Jingwen, Shi Yang, Shu Yongqian, Niu Zuoxing, Hara Hiroki, Wu Jun, Hsu Chih-Hung, Van Cutsem Eric, Brock Malcolm V, Zhang Zhang, Ding Ningning, Zhang Yun, Shen Zhirong, Shen Lin

Origin and de novo domestication of sweet orange

甜橙的起源和从头驯化

Liu, Shengjun; Xu, Yuantao; Yang, Kun; Huang, Yue; Lu, Zhihao; Chen, Shulin; Gao, Xiang; Xiao, Gongao; Chen, Peng; Zeng, Xiuli; Wang, Lun; Zheng, Weikang; Liu, Zishuang; Liao, Guanglian; He, Fa; Liu, Junjie; Wan, Pengfei; Ding, Fang; Ye, Junli; Jiao, Wenbiao; Chai, Lijun; Pan, Zhiyong; Zhang, Fei; Lin, Zongcheng; Zan, Yanjun; Guo, Wenwu; Larkin, Robert M; Xie, Zongzhou; Wang, Xia; Deng, Xiuxin; Xu, Qiang

Author Correction: Origin and de novo domestication of sweet orange

作者更正:甜橙的起源和从头驯化

Liu, Shengjun; Xu, Yuantao; Yang, Kun; Huang, Yue; Lu, Zhihao; Chen, Shulin; Gao, Xiang; Xiao, Gongao; Chen, Peng; Zeng, Xiuli; Wang, Lun; Zheng, Weikang; Liu, Zishuang; Liao, Guanglian; He, Fa; Liu, Junjie; Wan, Pengfei; Ding, Fang; Ye, Junli; Jiao, Wenbiao; Chai, Lijun; Pan, Zhiyong; Zhang, Fei; Lin, Zongcheng; Zan, Yanjun; Guo, Wenwu; Larkin, Robert M; Xie, Zongzhou; Wang, Xia; Deng, Xiuxin; Xu, Qiang

Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers

对14个开展手术的中心中食管癌患者的疾病特征和治疗模式进行回顾性分析

Lu, Zhihao; Geng, Mingfei; Han, Yongtao; Cao, Jianzhong; Wang, Jun; Liu, Tianshu; Yuan, Xianglin; Meng, Xue; Zhang, Yanqiao; Zhao, Rong; Wan, Lixin; Li, Enxiao; Wang, Wenran; Li, Zhijie; Shi, Danfeng; Qian, Jing; Shi, Si; Dong, Fengshi; Shen, Lin

Development and validation of a clinical risk-prediction model for immune checkpoint inhibitor-related pneumonitis in patients with gastrointestinal cancer based on four machine learning algorithms

基于四种机器学习算法,开发并验证用于预测胃肠道癌症患者免疫检查点抑制剂相关性肺炎临床风险的模型

Wang, Yixuan; Zhang, Liyan; Su, Zhenzhen; Lian, Xuemin; Lu, Zhihao